Clinical Nuclear Medicine

Skip Navigation LinksHome > April 2012 - Volume 37 - Issue 4 > Normal Uptake of 68Ga-DOTA-TOC by the Pancreas Uncinate Proc...
Clinical Nuclear Medicine:
doi: 10.1097/RLU.0b013e3182485110
Original Articles

Normal Uptake of 68Ga-DOTA-TOC by the Pancreas Uncinate Process Mimicking Malignancy at Somatostatin Receptor PET

Jacobsson, Hans MD, PhD*,†; Larsson, Patricia MD*,†; Jonsson, Cathrine PhD; Jussing, Emma MPharm; Grybäck, Per MD, PhD*,†

Collapse Box


Purpose: To characterize a commonly occurring increased uptake by the uncinate process of the pancreas at PET/CT using 68Ga-DOTA-d-Phe1-Tyr3-octreotide (68Ga-DOTA-TOC). This tracer has replaced 111In pentetreotide (OctreoScan®) for somatostatin receptor scintigraphy at our laboratory.

Methods: Fifty of our first 74 PET/CT examinations with 68Ga-DOTA-TOC could be evaluated in retrospect. None of these patients had surgery or showed any pathology in the pancreas head at the concomitant CT.

Results: Thirty-five of the 50 examinations (70%) showed an uptake by the uncinate process sufficiently intense to be interpreted as pathologic and simulating a tumor. Mean SUVmax was 9.2. Mean SUVmean using an isoactivity cut-off of >75% and >50% was 7.8 and 6.0, respectively. Volume calculations of the uncinate process activity using these definitions gave 0.9 mL and 4.2 mL, respectively.

Conclusion: There is a frequent physiological uptake of 68Ga-DOTA-TOC by the pancreas uncinate process. This may be caused by an accumulation of pancreatic polypeptide-containing cells expressing somatostatin receptors. If there is a normal finding at concomitant diagnostic CT, this uptake should be regarded as physiological.

© 2012 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.